Organization (Industry)
Taiho Oncology (United States)
ClinicalTrials.gov lists Taiho Oncology (United States) as lead sponsor of 66 trials. It has 154 active development programs and 19 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs. 1 trial is registered to start in 2027 or later.
This page covers Taiho Oncology (United States): 66 lead-sponsored trials and 1 legal-entity registration.
Disease areas (49)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Lung Neoplasms | 10 |
| Carcinoma, Non-Small-Cell Lung | 9 |
| Leukemia, Myeloid, Acute | 8 |
| Colorectal Neoplasms | 7 |
| Myelodysplastic Syndromes | 7 |
Showing 5 of 49 disease areas.
Trials by start year as sponsor or collaborator (20)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 7 |
| 2022 | 5 |
| 2021 | 8 |
| 2020 | 6 |
| 2019 | 7 |
| 2018 | 4 |
| 2017 | 6 |
Showing 10 of 20 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 8 trials still running at the 2026-10-09 snapshot; registered median of 31 months across 52 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (154)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Zipalertinib | Lung Neoplasms | Phase 3 | 3 |
| Zipalertinib | Carcinoma, Non-Small-Cell Lung | Phase 3 | 3 |
| TAS 102 | Colorectal Neoplasms | Phase 3 | 2 |
| S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm) | Stomach Neoplasms | Phase 3 | 2 |
| TAS 102 | Stomach Neoplasms | Phase 3 | 1 |
Showing 5 of 154 active programs.
Approved assets (19)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Futibatinib | 9 |
| CISPLATIN | 3 |
| BEVACIZUMAB | 2 |
| GEMCITABINE | 1 |
| Venetoclax | 2 |
Showing 5 of 19 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 37% hit target (n=30) | 37% on time (n=30) |
Journals published in (50)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 14 |
| JCO precision oncology | 13 |
| Cancer chemotherapy and pharmacology | 5 |
| European journal of cancer (Oxford, England : 1990) | 5 |
| Cancer research | 4 |
Showing 5 of 50 journals.
FDA untitled letters (1)
| Issue date | Letter |
|---|---|
| 2025-03-21 | 185959 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 2 |
Organization relationships (10)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Iqvia Holdings Inc. | Uses vendor | 8 |
| National Comprehensive Cancer Network | Co sponsors trial with | 3 |
| Roche (Switzerland) | Co sponsors trial with | 2 |
| American Society of Clinical Oncology | Co sponsors trial with | 1 |
| Bayer (Germany) | Co sponsors trial with | 1 |
Showing 5 of 10 relationships.
Latest dated events (86)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-06-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-24 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-22 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-22 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 86 events.
Biomarker capability evidence (240)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 240 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.